There are reports that anti-BCMA CAR-T therapy can serve as a salvage treatment in patients with other autoimmune diseases who failed anti-CD19 CAR-T infusion, suggesting that PC depletion may improve outcomes in refractory cases [79]. This evidence concerns the gene CD19 and autoimmune disease.